Managing Treatment Side Effects in Advanced Breast Cancer

Seminars in Oncology Nursing

Volumn 23, Issue SUPPL. 2, 2007, Pages

  Moore, Susan ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; TRASTUZUMAB;

ARTICLE; BREAST TUMOR; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED DISORDER; DRUG TOXICITY; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; SKIN DISEASE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; DRUG TOXICITY; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; INFUSIONS, INTRAVENOUS; SKIN DISEASES;

EID: 36549010434     PISSN: 07492081     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.soncn.2007.10.005     Document Type: Article

References (32)

1. Kris M.G., Hesketh P.J., Somerfield M.R., et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 24 (2006) 2932-2947
2. Bender C.M., McDaniel R.W., Murphy-Ende K., et al. Chemotherapy-induced nausea and vomiting. Clin J Oncol Nurs 6 (2002) 94-102
3. Marse H., Van Cutsem E., Grothey A., et al. Management of adverse events and other practical considerations in patients receiving capecitabine (Xeloda). Eur J Oncol Nurs 8 suppl 1 (2004) S16-S30
4. Engelking C. Diarrhea. In: Yarbro C.H., Frogge M.H., and Goodman M. (Eds). Cancer symptom management. Ed 3 (2004), Jones and Bartlett, Boston, MA 528-550
5. Benson III A.B., Ajani J.A., Catalano R.B., et al. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol 22 (2004) 2918-2926
6. Saltz L.B. Understanding and managing chemotherapy-induced diarrhea. J Support Oncol 1 (2003) 35-46
7. Tykerb. [package insert] (2007), GlaxoSmithKline, Research Triangle Park, NC
8. Moy B., and Goss P.E. Lapatinib-associated toxicity and practical management recommendations. Oncologist 12 (2007) 756-765
9. Davison D. Oral mucositis. Clin J Oncol Nurs 10 (2006) 283-284
10. Oncology Nursing Society. Measuring oncology nursing-sensitive patient outcomes: evidence-based summary. Available at: http://onsopcontent.ons.org/toolkits/evidence/Clinical/pdf/MucositisSummary.pdf (accessed Septenber 28, 2007).
11. Oncology Nursing Society. PEP Resource Vol II: Mucositis. Available at: http://www.ons.org/outcomes/volume2/mucositis.shtml (accessed September 28, 2007).
12. Eilers J., and Million R. Prevention and management of oral mucositis in patients with cancer. Semin Oncol Nurs 23 (2007) 201-212
13. Rubenstein E.B., Peterson D.E., Schubert M., et al. Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 100 suppl 9 (2004) 2026-2046
14. Wilkes G.M., and Doyle D. Palmar-plantar erythrodysesthesia. Clin J Oncol Nurs 9 (2005) 103-106
15. Lassere Y., and Hoff P. Management of hand-foot syndrome in patients treated with capecitabine (Xeloda). Eur J Oncol Nurs 8 suppl 1 (2004) S31-S40
16. Pike K. Hand-foot syndrome. Oncol Nurs Forum 28 (2001) 1519-1520
17. Marse H., Van Cutsem E., Grothey A., et al. Management of adverse events and other practical considerations in patients receiving capecitabine (Xeloda). Eur J Oncol Nurs 8 suppl 1 (2004) S16-S30
18. Dick S., and Crawford G. Managing cutaneous side effects of epidermal growth factor receptor (HER1/EGFR) inhibitors. Community Oncol 2 (2005) 492-496
19. Perez-Soler R., Delord J.P., Halpern A., et al. HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist 10 (2005) 345-356
20. Morse L., and Calarese P. EGFR-targeted therapy and related skin toxicity. Semin Oncol Nurs 22 (2006) 152-162
21. Lacouture M.E., Basti S., Patel J., et al. The SERIES clinic: an interdisciplinary approach to the management of toxicities of EGFR inhibitors. J Support Oncol 4 (2006) 236-238
22. Sipples R. Common side effects of anti-EGFR therapy: acneform rash. Semin Oncol Nurs 22 suppl 1 (2006) 28-34
23. Fish-Steagall A., Searcy P., and Sipples R. Clinical experience with anti-EGFR therapy. Semin Oncol Nurs 22 suppl 1 (2006) 10-19
24. Segaert S., and Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 16 (2005) 1425-1433
25. DeWitt C.A., Siroy A.E., and Stone S.P. Acneiform eruptions associated with epidermal growth factor receptor-targeted chemotherapy. J Am Acad Dermatol 56 (2007) 500-505
26. Burris III H.A., Hurwitz H.I., Dees E.C., et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 23 (2005) 5305-5313
27. Robert C., Soria J.C., Spatz A., et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 6 (2005) 491-500
28. Montagut C., Grau J.J., Grimalt R., et al. Abnormal hair growth in a patient with head and neck cancer treated with the anti-epidermal growth factor receptor monoclonal antibody cetuximab. J Clin Oncol 23 (2005) 5273-5275
29. Perez-Soler R., and Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?. J Clin Oncol 23 (2005) 5235-5246
30. Herceptin package insert (2006), Genentech, Inc., South San Francisco, CA
31. Perez E.A., Byrne J.A., Hammond I.W., et al. Results of an analysis of cardiac function in 2,812 patients treated with lapatinib. J Clin Oncol 24 suppl 18S (2006) 583
32. Ewer M.S., Vooletich M.T., Durand J.B., et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol 23 (2005) 7820-7826